GeoVax Labs, Inc. Share Price & Technical Analysis
GOVX · $3.64 (+32.36%)
Healthcare / Biotechnology
$3.64
+32.36%
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marbu…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
227% return in May, 9% avg return in past 3 year May month.
114% return in 2026, -72% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -36% | -43% | -12% | -21% | 227% | – | – | – | – | – | – | – | 114% |
| 25 | -25% | -23% | -36% | -8% | -1% | -18% | 27% | 4% | -36% | 13% | -27% | -58% | -188% |
| 24 | -41% | -24% | -22% | -30% | 25% | 70% | -36% | 115% | -47% | -18% | 32% | -8% | 17% |
| 23 | 28% | -17% | -6% | -5% | 2% | -10% | 5% | 1% | -10% | -5% | -13% | -16% | -46% |
| 22 | -35% | -28% | -37% | -31% | 126% | -53% | 228% | -72% | -4% | -18% | -16% | -18% | 42% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Overbought
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$3.98M
P/E ratio
—
52W high
$34.75
52W low
$0.96
Volume
4,54,54,362
Beta
3.35
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is GeoVax Labs, Inc. share price today?
- GeoVax Labs, Inc. (GOVX) last traded around $3.64 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GOVX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GOVX. Download the app for real-time alerts.
- How can I analyze GeoVax Labs, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.